

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6019106

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	04/11/2018
RESUBMIT DOCUMENT ID:	505679627

CONVEYING PARTY DATA

Name	Execution Date
THE SECRETARY OF STATE FOR HEALTH	04/11/2018

RECEIVING PARTY DATA

Name:	SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE
Street Address:	39 VICTORIA STREET
Internal Address:	MINISTERIAL CORRESPONDENCE AND PUBLIC ENQUIRIES, DEPARTMENT OF HEALTH AND SOCIAL CARE
City:	LONDON
State/Country:	UNITED KINGDOM
Postal Code:	SW1 0EU

PROPERTY NUMBERS Total: 38

Property Type	Number
Application Number:	12758315
Application Number:	09889520
Application Number:	15130749
Application Number:	14390528
Application Number:	16324107
Application Number:	13958335
Application Number:	13143722
Application Number:	15309348
Application Number:	12377041
Application Number:	14363533
Application Number:	10541716
Application Number:	12664218
Application Number:	14053426
Application Number:	15304025
Application Number:	15672085
Application Number:	15205841
Application Number:	12918628

PATENT

Property Type	Number
Application Number:	13776316
Application Number:	10599098
Application Number:	15098949
Application Number:	13699394
Application Number:	15761012
Application Number:	12302752
Application Number:	16096917
Application Number:	13977399
Application Number:	14763622
Application Number:	16511503
Application Number:	13878150
Application Number:	13513555
Application Number:	15549933
Application Number:	11153865
Application Number:	12042150
Application Number:	13246659
Application Number:	13534911
Application Number:	14652714
Application Number:	14218854
Application Number:	13202557
Application Number:	16335830

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: rmgreenshields@mathys-squire.com

Correspondent Name: MATHYS & SQUIRE LLP

Address Line 1: THE SHARD

Address Line 2: 32 LONDON BRIDGE STREET

Address Line 4: LONDON, UNITED KINGDOM SE1 9SG

ATTORNEY DOCKET NUMBER:	I27032-RMG
NAME OF SUBMITTER:	RICHARD GREENSHIELDS
SIGNATURE:	/Richard Greenshields/
DATE SIGNED:	03/18/2020

Total Attachments: 53
source=COnf Ass Patents#page1.tif
source=COnf Ass Patents#page2.tif
source=COnf Ass Patents#page3.tif
source=COnf Ass Patents#page4.tif

source=COnf Ass Patents#page5.tif
source=COnf Ass Patents#page6.tif
source=COnf Ass Patents#page7.tif
source=COnf Ass Patents#page8.tif
source=COnf Ass Patents#page9.tif
source=COnf Ass Patents#page10.tif
source=COnf Ass Patents#page11.tif
source=COnf Ass Patents#page12.tif
source=COnf Ass Patents#page13.tif
source=COnf Ass Patents#page14.tif
source=COnf Ass Patents#page15.tif
source=COnf Ass Patents#page16.tif
source=COnf Ass Patents#page17.tif
source=COnf Ass Patents#page18.tif
source=COnf Ass Patents#page19.tif
source=COnf Ass Patents#page20.tif
source=COnf Ass Patents#page21.tif
source=COnf Ass Patents#page22.tif
source=COnf Ass Patents#page23.tif
source=COnf Ass Patents#page24.tif
source=COnf Ass Patents#page25.tif
source=COnf Ass Patents#page26.tif
source=COnf Ass Patents#page27.tif
source=COnf Ass Patents#page28.tif
source=COnf Ass Patents#page29.tif
source=COnf Ass Patents#page30.tif
source=COnf Ass Patents#page31.tif
source=COnf Ass Patents#page32.tif
source=COnf Ass Patents#page33.tif
source=COnf Ass Patents#page34.tif
source=COnf Ass Patents#page35.tif
source=COnf Ass Patents#page36.tif
source=COnf Ass Patents#page37.tif
source=COnf Ass Patents#page38.tif
source=COnf Ass Patents#page39.tif
source=COnf Ass Patents#page40.tif
source=COnf Ass Patents#page41.tif
source=COnf Ass Patents#page42.tif
source=COnf Ass Patents#page43.tif
source=COnf Ass Patents#page44.tif
source=COnf Ass Patents#page45.tif
source=COnf Ass Patents#page46.tif
source=COnf Ass Patents#page47.tif
source=COnf Ass Patents#page48.tif
source=COnf Ass Patents#page49.tif
source=COnf Ass Patents#page50.tif
source=COnf Ass Patents#page51.tif
source=COnf Ass Patents#page52.tif

THIS CONFIRMATION OF ASSIGNMENT is made

Between:

- (1) The Secretary of State for Health
Richmond House
79 Whitehall
London SW1A 2NS
United Kingdom
(hereinafter "the Assignor"), and
- (2) Secretary of State for Health and Social Care
Ministerial Correspondence and Public Enquiries
Department of Health and Social Care
39 Victoria Street
London SW1H 0EU
United Kingdom
(hereinafter "the Assignee")

Whereas:

- (A) The Assignor is registered as applicant/proprietor in respect of the patents and patent applications and associated know-how/confidential information identified in the Schedule (hereinafter the "Patents").
- (B) All rights, title and interest in the Patents were transferred from the Assignor to the Assignee by virtue of Statutory Instrument 2018 No. 378 ("The Secretaries of State for Health and Social Care and for Housing, Communities and Local Government and Transfer of Functions (Commonhold Land) Order 2018"), copy attached as Annex A.
- (C) The Assignee accepts the assignment of the Patents.
- (D) The effective date of the assignment is 11 April 2018.
- (E) The parties wish to confirm the assignment for the purposes of recording the assignment at the national Intellectual Property Offices.

Operative provisions:

- 1 In consideration of the sum of one pound sterling paid by the Assignee to the Assignor, the receipt of which is hereby acknowledged, the Assignor hereby confirms the assignment of all of its property, right, title and interest in and to the Patents and each and every invention disclosed therein to the Assignee to hold absolutely for the benefit of the Assignee, their successors or assigns including, for the avoidance of any doubt the right to claim priority and/or file new applications therefrom and including all continuation applications, continuation-in-part applications, re-examination applications, registration applications, divisional applications, requests for patent term extensions and patent term adjustments (PTE), and Supplementary Protection Certificate (SPC) applications, together with the initiation or defence of interferences, the initiation or defence of oppositions and other similar proceedings and any appeals

therefrom, in particular fulfilling requirements for obtaining SPCs or PTEs, and to bring all such proceedings as may be necessary for the recovery of, damages or other forms of relief in respect of any and all infringements of the Patents and Patents resulting from any continuation applications, continuation-in-part applications, re-examination applications, registration applications, divisional applications, requests for patent term extensions and patent term adjustments (PTE), and Supplementary Protection Certificate (SPC) resulting from the Patents whether taking place before or after the effective date of this assignment TO HOLD the same unto the Assignee absolutely.

- 2 The Assignor HEREBY COVENANTS that it will at the expense of the Assignee execute, sign and do all such instruments, applications, documents, acts and things as may reasonably be required by the Assignee to enable the Assignee, the nominees of the Assignee, their successors or assigns to enjoy the full benefit of the property and rights hereby assigned and to enjoy the exclusive benefit of any extension, prolongation or further grant of patents for the time being vested in the Assignee by virtue of this Assignment.

Schedule

Case Ref.	Country	Application No.	Application Date	Patent No.	Grant Date	Title	Case Status
P20808US-C3-PCT	United States of America	12/758315	02-Nov-1999			Multicomponent meningococcal vaccine	Pending
P21131AU-PCT	Australia	23071/00	03-Feb-2000	774580	21-Oct-2004	Assay with reduced background	Granted
P21131CA-PCT	Canada	2360779	03-Feb-2000	TMA2360779	27-Apr-2010	Assay with reduced background	Granted
P21131CHL-EPC-PCT	Switzerland & Liechtenstein	00901771.6	03-Feb-2000	1151087	07-May-2008	Assay with reduced background	Granted
P21131DE-EPC-PCT	Germany	00901771.6	03-Feb-2000	1151087	07-May-2008	Assay with reduced background	Granted
P21131ES-EPC-PCT	Spain	00901771.6	03-Feb-2000	1151087	07-May-2008	Assay with reduced background	Granted
P21131FR-EPC-PCT	France	00901771.6	03-Feb-2000	1151087	07-May-2008	Assay with reduced background	Granted
P21131IT-EPC-PCT	Italy	00901771.6	03-Feb-2000	1151087	07-May-2008	Assay with reduced background	Granted
P21131NL-EPC-PCT	Netherlands	00901771.6	03-Feb-2000	1151087	07-May-2008	Assay with reduced background	Granted
P21131US-PCT	United States of America	09/889520	03-Feb-2000	6913896	05-Jul-2005	Assay with reduced background	Granted
P24090CHL-EPC-PCT	Switzerland & Liechtenstein	04701383.4	12-Jan-2004	1587520	12-Aug-2009	Bacteriophage for the treatment of bacterial biofilms	Granted
P24090DE-EPC-PCT	Germany	04701383.4	12-Jan-2004	1587520	12-Aug-2009	Bacteriophage for the treatment of bacterial biofilms	Granted
P24090FR-EPC-PCT	France	04701383.4	12-Jan-2004	1587520	12-Aug-2009	Bacteriophage for the treatment of bacterial biofilms	Granted

P24090NL-EPC-PCT	Netherlands	04701383.4	12-Jan-2004	1587520	12-Aug-2009	Bacteriophage for the treatment of bacterial biofilms	Granted
P24090US-PCT	United States of America	10/541716	12-Jan-2004	7758856	20-Jul-2010	Bacteriophage for the treatment of bacterial biofilms	Granted
P26205AT-EPC-PCT	Austria	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205AU-PCT	Australia	2005225596	22-Mar-2005	2005225596	18-Jun-2010	Biological indicator	Granted
P26205BE-EPC-PCT	Belgium	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205CA-PCT	Canada	2558359	22-Mar-2005	2558359	04-Nov-2014	Thermostable kinase as an indicator for validating a treatment process for reducing the amount or activity of a contaminating biological agent in a sample	Granted
P26205CHL-EPC-PCT	Switzerland & Liechtenstein	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205CN-D1-PCT	China	201110045849.7	22-Mar-2005	ZL201110045849.7	24-Apr-2018	Biological indicator	Granted
P26205DE-EPC-PCT	Germany	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205ES-EPC-PCT	Spain	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205FR-EPC-PCT	France	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205HK-PCT	Hong Kong	07104976.3	22-Mar-2005	1097576	16-Dec-2011	Biological indicator	Granted
P26205IE-EPC-PCT	Ireland	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205IN-PCT	India	3014/KOLNP/2006	22-Mar-2005			Biological indicator	Pending
P26205IT-EPC-PCT	Italy	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205JP-PCT	Japan	2007-504461	22-Mar-2005	4774039	01-Jul-2011	Biological indicator	Granted

P26205NL-EPC-PCT	Netherlands	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205PL-EPC-PCT	Poland	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205SE-EPC-PCT	Sweden	05718095.2	22-Mar-2005	1756296	27-Jul-2011	Biological indicator	Granted
P26205US-D2-PCT	United States of America	13/776316	22-Mar-2005	9102976	11-Aug-2015	Biological indicator	Granted
P26205US-PCT	United States of America	10/599098	22-Mar-2005	8389208	05-Mar-2013	Biological indicator	Granted
P26205ZA-PCT	South Africa	2006/07193	22-Mar-2005	2006/07193	27-Aug-2008	Biological indicator	Granted
P26512AU-PCT	Australia	2005254774	16-Jun-2005	2005254774	21-Apr-2011	Preparation of protective antigen from Bacillus anthracis	Granted
P26512CA-PCT	Canada	2570508	16-Jun-2005	2570508	16-Dec-2014	Preparation of protective antigen from Bacillus anthracis	Granted
P26512DE-EPC-PCT	Germany	05751997.7	16-Jun-2005	1768995	13-Jun-2012	"Preparation of protective antigen from bacillus anthracis"	Granted
P26512FR-EPC-PCT	France	05751997.7	16-Jun-2005	1768995	13-Jun-2012	"Preparation of protective antigen from bacillus anthracis"	Granted
P26512JP-PCT	Japan	2007-516035	16-Jun-2005	5097544	28-Sep-2012	"Preparation of protective antigen from Bacillus anthracis"	Granted
P26512KR-PCT	Republic of Korea	10-2007-7001092	16-Jun-2005	10-1290619	23-Jul-2013	"Preparation of protective antigen from Bacillus anthracis"	Granted
P26512NL-EPC-PCT	Netherlands	05751997.7	16-Jun-2005	1768995	13-Jun-2012	"Preparation of protective antigen from bacillus anthracis"	Granted
P26512US-01	United States of America	11/153865	15-Jun-2005	7355027	08-Apr-2008	Bacillus anthracis protective antigen	Granted

P26512US-01-C1	United States of America	12/042150	15-Jun-2005	8101735	24-Jan-2012	"Preparation of protective antigen"	Granted
P26512US-01-C1-D1	United States of America	13/246659	15-Jun-2005	8323927	04-Dec-2012	"Preparation of protective antigen"	Granted
P26512US-01-C2-D1	United States of America	13/534911	15-Jun-2005	8440427	14-May-2013	Preparation of protective antigen	Granted
P26885AU-C1-PCT	Australia	2011202219	01-Dec-2005	2011202219	17-Sep-2015	Fusion proteins	Granted
P26885AU-C2-PCT	Australia	2012200046	01-Dec-2005	2012200046	17-Sep-2015	Fusion proteins	Granted
P26885AU-C3-PCT	Australia	2012201491	01-Dec-2005	2012201491	04-Jun-2015	Fusion proteins	Granted
P26885BE-D1-EPC-PCT	Belgium	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted
P26885BE-D2-EPC-PCT	Belgium	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885CHL-D1-EPC-PCT	Switzerland & Liechtenstein	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted
P26885CHL-D2-EPC-PCT	Switzerland & Liechtenstein	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885CZ-D1-EPC-PCT	Czechia	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted
P26885CZ-D2-EPC-PCT	Czechia	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885DE-D1-EPC-PCT	Germany	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted
P26885DE-D2-EPC-PCT	Germany	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885ES-D1-EPC-PCT	Spain	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted

P26885ES-D2-EPC-PCT	Spain	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885FR-D1-EPC-PCT	France	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted
P26885FR-D2-EPC-PCT	France	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885GB-D1-EPC-PCT	United Kingdom	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted
P26885GB-D2-EPC-PCT	United Kingdom	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885GR-D1-EPC-PCT	Greece	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted
P26885GR-D2-EPC-PCT	Greece	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885IE-D2-EPC-PCT	Ireland	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885IT-D1-EPC-PCT	Italy	10166556.0	01-Dec-2005	2366399	06-May-2015	Non-cytotoxic protein conjugates	Granted
P26885IT-D2-EPC-PCT	Italy	10184150.0	01-Dec-2005	2335718	17-Jun-2015	Non-cytotoxic protein conjugates	Granted
P26885JP-D2-PCT	Japan	236094/2012	01-Dec-2005	5739854	01-May-2015	"Fusion proteins"	Granted
P27211AU-C1-PCT	Australia	2011202225	01-Dec-2005	2011202225	03-Dec-2015	Non-cytotoxic protein conjugates	Granted
P27211BE-D2-EPC-PCT	Belgium	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211CA-PCT	Canada	2588292	01-Dec-2005			"Non-cytotoxic protein conjugates"	Pending

P27211CHL-D2-EPC-PCT	Switzerland & Liechtenstein	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211CZ-D2-EPC-PCT	Czechia	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211DE-D2-EPC-PCT	Germany	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211ES-D2-EPC-PCT	Spain	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211FR-D2-EPC-PCT	France	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211GB-D2-EPC-PCT	United Kingdom	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211GR-D2-EPC-PCT	Greece	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211IE-D2-EPC-PCT	Ireland	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211IT-D2-EPC-PCT	Italy	10184114.6	01-Dec-2005	2292249	03-Jun-2015	Non-cytotoxic protein conjugates	Granted
P27211JP-D1-PCT	Japan	2014-14941	01-Dec-2005	6027035	21-Oct-2016	Non-cytotoxic protein conjugates	Granted
P27211JP-D3-PCT	Japan	2016-100002	01-Dec-2005			Non-cytotoxic protein conjugates	Pending
P29010AU-PCT	Australia	2007266857	24-May-2007	2007266857	26-Apr-2013	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P29010CA-PCT	Canada	2652510	24-May-2007	2652510	07-Jul-2015	Mycoplasma genitalium detection assay based on the MG219 gene	Granted

P29010CHL-EPC-PCT	Switzerland & Liechtenstein	07732934.0	24-May-2007	2024510	25-Apr-2012	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P29010DE-EPC-PCT	Germany	07732934.0	24-May-2007	2024510	25-Apr-2012	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P29010FR-EPC-PCT	France	07732934.0	24-May-2007	2024510	25-Apr-2012	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P29010HK-PCT	Hong Kong	09102960.3	24-May-2007	1124789	21-Dec-2012	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P29010IE-EPC-PCT	Ireland	07732934.0	24-May-2007	2024510	25-Apr-2012	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P29010JP-PCT	Japan	2009-511576	24-May-2007	5674309	09-Jan-2015	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P29010NL-EPC-PCT	Netherlands	07732934.0	24-May-2007	2024510	25-Apr-2012	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P29010US-PCT	United States of America	12/302752	24-May-2007	8778611	15-Jul-2014	Mycoplasma genitalium detection assay based on the MG219 gene	Granted
P30041AT-EPC-PCT	Austria	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted

P30041AU-PCT	Australia	2009216579	18-Feb-2009	2009216579	26-Jun-2014	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041BE-EPC-PCT	Belgium	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041CA-PCT	Canada	2713421	18-Feb-2009	2713421	01-Nov-2016	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041CHL-EPC-PCT	Switzerland & Liechtenstein	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041CN-PCT	China	20098011388.3.4	18-Feb-2009	ZL20098011388.4	23-Mar-2016	"Covalently linked thermostable kinase for decontamination process validation"	Granted
P30041DE-EPC-PCT	Germany	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041ES-EPC-PCT	Spain	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted

P30041FR-EPC-PCT	France	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041IE-EPC-PCT	Ireland	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041IN-PCT	India	2770/KOLNP/2010	18-Feb-2009	297913	21-Jun-2018	"Covalently linked thermostable kinase for decontamination process validation"	Granted
P30041IT-EPC-PCT	Italy	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041JP-PCT	Japan	547256/2010	18-Feb-2009	5597552	15-Aug-2014	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041NL-EPC-PCT	Netherlands	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041PL-EPC-PCT	Poland	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted

P30041SE-EPC-PCT	Sweden	09712816.9	18-Feb-2009	2247749	26-Dec-2012	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041US-D1-PCT	United States of America	15/205841	18-Feb-2009	10466245	05-Nov-2019	"Covalently linked thermostable kinase for decontamination process validation"	Granted
P30041US-PCT	United States of America	12/918628	18-Feb-2009	9416396	16-Aug-2016	Covalently linked thermostable kinase for decontamination process validation	Granted
P30041ZA-PCT	South Africa	2010/05194	18-Feb-2009	2010/05194	29-Jun-2011	Covalently linked thermostable kinase for decontamination process validation	Granted
P30647GB-EPC-PCT	United Kingdom	08762559.6	13-Jun-2008	2167119	24-Aug-2016	Chemically modified peptides with improved immunogenicity	Granted
P30647US-PCT	United States of America	12/664218	13-Jun-2008	8883172	11-Nov-2014	Chemically modified peptides with improved immunogenicity	Granted
P31981AT-EPC-PCT	Austria	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981AU-PCT	Australia	2010204173	07-Jan-2010	2010204173	03-Mar-2016	"Rapid bioluminescence detection system"	Granted

P31981BE-EPC-PCT	Belgium	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981CA-PCT	Canada	2749021	07-Jan-2010	2749021	12-Jun-2018	Rapid bioluminescence detection system	Granted
P31981CHL-EPC-PCT	Switzerland & Liechtenstein	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981CN-PCT	China	201080008250.X	07-Jan-2010	ZL201080008250.X	14-Dec-2016	"Rapid bioluminescence detection system"	Granted
P31981DE-EPC-PCT	Germany	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981ES-EPC-PCT	Spain	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981FR-EPC-PCT	France	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981GB-EPC-PCT	United Kingdom	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981HK-PCT	Hong Kong	11112693.2	07-Jan-2010	1158272	21-Jul-2017	Rapid bioluminescence detection system	Granted
P31981IE-EPC-PCT	Ireland	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981IN-PCT	India	5370/DELNP/2011	07-Jan-2010			"Rapid bioluminescence detection system"	Pending

P31981IT-EPC-PCT	Italy	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981JP-PCT	Japan	2011-544086	07-Jan-2010	6042066	18-Nov-2016	"Rapid bioluminescence detection system"	Granted
P31981NL-EPC-PCT	Netherlands	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981PL-EPC-PCT	Poland	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981SE-EPC-PCT	Sweden	10700590.2	07-Jan-2010	2385988	25-May-2016	"Rapid bioluminescence detection system"	Granted
P31981US-C1-PCT	United States of America	13/958335	07-Jan-2010	9046523	02-Jun-2015	Rapid bioluminescence detection assay	Granted
P31981US-PCT	United States of America	13/143722	07-Jan-2010	8512970	20-Aug-2013	Rapid bioluminescence detection assay	Granted
P31981ZA-PCT	South Africa	2011/04929	07-Jan-2010	2011/04929	28-Mar-2012	"Rapid bioluminescence detection system"	Granted
P33088AU-PCT	Australia	2010215275	19-Feb-2010	2010215275	14-Jul-2016	"Antibodies to Clostridium difficile Toxins"	Granted
P33088EP-PCT	European Patent Office	10706731.6	19-Feb-2010			"Antibodies to Clostridium difficile Toxins"	Pending
P33088HK-PCT	Hong Kong	12100716.9	19-Feb-2010			Antibodies to Clostridium difficile Toxins	Pending

P33088US-C1-PCT	United States of America	14/218854	19-Feb-2010			"Antibodies to Clostridium difficile Toxins"	Pending
P33088US-PCT	United States of America	13/202557	19-Feb-2010	8709428	29-Apr-2014	Antibodies to Clostridium difficile Toxins	Granted
P33260AU-PCT	Australia	2011311321	05-Oct-2011	2011311321	01-Sep-2016	"Clostridium difficile Antigens"	Granted
P33260CA-PCT	Canada	2812731	05-Oct-2011			Clostridium difficile Antigens	Pending
P33260CHL-EPC-PCT	Switzerland & Liechtenstein	11769913.2	05-Oct-2011	2625193	04-Apr-2018	Clostridium difficile Antigens	Granted
P33260CN-PCT	China	20118004791 3.3	05-Oct-2011	20118004791 3.3	26-Oct-2016	"Clostridium difficile Antigens"	Granted
P33260DE-EPC-PCT	Germany	11769913.2	05-Oct-2011	2625193	04-Apr-2018	Clostridium difficile Antigens	Granted
P33260FR-EPC-PCT	France	11769913.2	05-Oct-2011	2625193	04-Apr-2018	Clostridium difficile Antigens	Granted
P33260GB-EPC-PCT	United Kingdom	11769913.2	05-Oct-2011	2625193	04-Apr-2018	Clostridium difficile Antigens	Granted
P33260HK-PCT	Hong Kong	13112192.6	05-Oct-2011	1185621	14-Sep-2018	Clostridium difficile Antigens	Granted
P33260IE-EPC-PCT	Ireland	11769913.2	05-Oct-2011	2625193	04-Apr-2018	Clostridium difficile Antigens	Granted
P33260IN-PCT	India	720/MUMNP/2013	05-Oct-2011			"Clostridium difficile Antigens"	Pending
P33260JP-PCT	Japan	2013-532271	05-Oct-2011	6377907	03-Aug-2018	"Clostridium difficile Antigens"	Granted
P33260SG-PCT	Singapore	201302150-6	05-Oct-2011	189058	21-May-2018	Clostridium difficile Antigens	Granted
P33260US-D1-PCT	United States of America	16/511503	05-Oct-2011			Clostridium difficile Antigens	Pending
P33260US-PCT	United States of America	13/878150	05-Oct-2011	10369206	06-Aug-2019	Clostridium difficile Antigens	Granted
P33528AU-PCT	Australia	2015207374	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending

P33528BR-PCT	Brazil	BR112016016103-3	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending
P33528CA-PCT	Canada	2936051	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending
P33528CN-PCT	China	201580009239.8	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending
P33528EP-D1-PCT	European Patent Office	17192244.6	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending
P33528HK-D1-PCT	Hong Kong	18106887.3	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending
P33528IN-PCT	India	201617024386	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending
P33528RU-PCT	Russian Federation	2016133598	16-Jan-2015	2702194	04-Oct-2019	"Mycobacterial Antigen Composition"	Granted
P33528US-D1-PCT	United States of America	15/672085	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending
P33528ZA-PCT	South Africa	2016/05606	16-Jan-2015			"Mycobacterial Antigen Composition"	Pending
P33833AU-PCT	Australia	2010325764	06-Dec-2010	2010325764	14-Jul-2016	"Therapies for preventing or suppressing Clostridium difficile infection"	Granted
P33833CA-PCT	Canada	2782639	06-Dec-2010	2782639	26-Feb-2019	"Therapies for preventing or suppressing Clostridium difficile infection"	Granted

P33833CN-PCT	China	20108005377 8.9	06-Dec-2010			Therapies for preventing or suppressing Clostridium difficile infection	Pending
P33833EP-PCT	European Patent Office	10787170.9	06-Dec-2010			"Therapies for preventing or suppressing Clostridium difficile infection"	Pending
P33833HK-PCT	Hong Kong	13100297.5	06-Dec-2010			Therapies for preventing or suppressing Clostridium difficile infection	Pending
P33833IN-PCT	India	4333/DELNP/2012	06-Dec-2010			"Therapies for preventing or suppressing Clostridium difficile infection"	Pending
P33833MY-PCT	Malaysia	PI 2012002466	06-Dec-2010	MY-158712-A	15-Nov-2016	"Therapies for preventing or suppressing Clostridium difficile infection"	Granted
P33833SG-PCT	Singapore	201203961-6	06-Dec-2010	181127	26-Oct-2016	"Therapies for preventing or suppressing Clostridium difficile infection"	Granted
P33833US-PCT	United States of America	13/513555	06-Dec-2010	8921529	30-Dec-2014	"Therapies for preventing or suppressing Clostridium difficile infection"	Granted

P35217AU-PCT	Australia	2011254348	23-May-2011	2011254348	27-Nov-2014	Mycobacterial antigen composition	Granted
P35217BR-PCT	Brazil	112012029643-4	23-May-2011			Mycobacterial antigen composition	Pending
P35217CA-PCT	Canada	2800139	23-May-2011			Mycobacterial antigen composition	Pending
P35217CHL-EPC-PCT	Switzerland & Liechtenstein	11721352.0	23-May-2011	2571518	16-Dec-2015	Mycobacterial antigen composition	Granted
P35217CN-PCT	China	201180025286.3	23-May-2011	ZL201180025286.3	29-Apr-2015	Mycobacterial antigen composition	Granted
P35217DE-EPC-PCT	Germany	11721352.0	23-May-2011	2571518	16-Dec-2015	Mycobacterial antigen composition	Granted
P35217FR-EPC-PCT	France	11721352.0	23-May-2011	2571518	16-Dec-2015	Mycobacterial antigen composition	Granted
P35217GB-EPC-PCT	United Kingdom	11721352.0	23-May-2011	2571518	16-Dec-2015	Mycobacterial antigen composition	Granted
P35217IN-PCT	India	9470/DELNP/2012	23-May-2011			Mycobacterial antigen composition	Pending
P35217NL-EPC-PCT	Netherlands	11721352.0	23-May-2011	2571518	16-Dec-2015	Mycobacterial antigen composition	Granted
P35217RU-PCT	Russian Federation	2012155702	23-May-2011	2576007	27-Feb-2016	Mycobacterial antigen composition	Granted
P35217US-C1-PCT	United States of America	15/098949	23-May-2011	9982039	29-May-2018	Mycobacterial antigen composition	Granted
P35217US-PCT	United States of America	13/699394	23-May-2011	9339534	17-May-2016	Mycobacterial antigen composition	Granted
P35217ZA-PCT	South Africa	2012/08093	23-May-2011	2012/08093	26-Jun-2013	Mycobacterial antigen composition	Granted
P36821GB-EPC-PCT	United Kingdom	12761794.2	14-Sep-2012	2756081	01-Jul-2015	Thermostable assay reagents	Granted

P37063AT-EPC-PCT	Austria	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063AU-PCT	Australia	2012300592	03-Sep-2012	2012300592	11-Jan-2018	Influenza virus antibody compositions	Granted
P37063BE-EPC-PCT	Belgium	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063BR-PCT	Brazil	BR112014004860.6	03-Sep-2012			Influenza virus antibody compositions	Pending
P37063CA-PCT	Canada	2847263	03-Sep-2012			Influenza virus antibody compositions	Pending
P37063CHL-EPC-PCT	Switzerland & Liechtenstein	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063CN-PCT	China	201280053282.0	03-Sep-2012	ZL201280053282.0	29-Mar-2019	Influenza virus antibody compositions	Granted
P37063DE-EPC-PCT	Germany	602012050116.2	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063DK-EPC-PCT	Denmark	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063EP-D1-PCT	European Patent Office	18183550.5	03-Sep-2012			Influenza virus antibody compositions	Pending
P37063ES-EPC-PCT	Spain	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted

P37063FI-EPC-PCT	Finland	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063FR-EPC-PCT	France	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063GB-EPC-PCT	United Kingdom	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063IE-EPC-PCT	Ireland	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063IN-PCT	India	1597/DELNP/2014	03-Sep-2012			Influenza virus antibody compositions	Pending
P37063IT-EPC-PCT	Italy	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063JP-PCT	Japan	2014/527742	03-Sep-2012	6279469	26-Jan-2018	Influenza virus antibody compositions	Granted
P37063NL-EPC-PCT	Netherlands	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063SE-EPC-PCT	Sweden	12756552.1	03-Sep-2012	2750708	22-Aug-2018	"Influenza virus antibody compositions"	Granted
P37063US-PCT	United States of America	14/342376	03-Sep-2012	9771415	26-Sep-2017	"Influenza virus antibody compositions"	Granted
P37511AU-PCT	Australia	2012349863	10-Dec-2012	2012349863	26-Oct-2017	"Respiratory infection assay"	Granted
P37511BR-PCT	Brazil	BR112014013825-7	10-Dec-2012			"Respiratory infection assay"	Pending

P37511CA-PCT	Canada	2858009	10-Dec-2012			"Respiratory infection assay"	Pending
P37511CHL-EPC-PCT	Switzerland & Liechtenstein	12806635.4	10-Dec-2012	2788503	25-Nov-2015	"Respiratory infection assay"	Granted
P37511CN-PCT	China	20128006071 0.2	10-Dec-2012	ZL2012800607 10.2	23-Mar-2016	Respiratory infection assay	Granted
P37511DE-EPC-PCT	Germany	12806635.4	10-Dec-2012	2788503	25-Nov-2015	"Respiratory infection assay"	Granted
P37511FR-EPC-PCT	France	12806635.4	10-Dec-2012	2788503	25-Nov-2015	"Respiratory infection assay"	Granted
P37511GB-EPC-PCT	United Kingdom	12806635.4	10-Dec-2012	2788503	25-Nov-2015	"Respiratory infection assay"	Granted
P37511IE-EPC-PCT	Ireland	12806635.4	10-Dec-2012	2788503	25-Nov-2015	"Respiratory infection assay"	Granted
P37511IN-PCT	India	1125/MUMN P/2014	10-Dec-2012			"Respiratory infection assay"	Pending
P37511IT-EPC-PCT	Italy	12806635.4	10-Dec-2012	2788503	25-Nov-2015	"Respiratory infection assay"	Granted
P37511JP-PCT	Japan	2014-545362	10-Dec-2012	6421037	19-Oct-2018	"Respiratory infection assay"	Granted
P37511NL-EPC-PCT	Netherlands	12806635.4	10-Dec-2012	2788503	25-Nov-2015	"Respiratory infection assay"	Granted
P37511RU-PCT	Russian Federation	2014127865	10-Dec-2012	2642304	24-Jan-2018	"Respiratory infection assay"	Granted
P37511US-PCT	United States of America	14/363533	10-Dec-2012	10294534	21-May-2019	Respiratory infection assay	Granted
P37731GB-EPC-PCT	United Kingdom	13715734.3	05-Apr-2013	2834278	15-Mar-2017	Decontaminant Product and Method	Granted
P38317CHL-EPC-PCT	Switzerland & Liechtenstein	13715732.7	04-Apr-2013	2844283	12-Jun-2019	Clostridium difficile antigens	Granted
P38317DE-EPC-PCT	Germany	13715732.7	04-Apr-2013	2844283	12-Jun-2019	Clostridium difficile antigens	Granted
P38317EP-PCT	European Patent Office	13715732.7	04-Apr-2013	2844283	12-Jun-2019	Clostridium difficile antigens	Granted
P38317FR-EPC-PCT	France	13715732.7	04-Apr-2013	2844283	12-Jun-2019	Clostridium difficile antigens	Granted

P38317GB-EPC-PCT	United Kingdom	13715732.7	04-Apr-2013	2844283	12-Jun-2019	Clostridium difficile antigens	Granted
P38317HK-PCT	Hong Kong	15103423.4	04-Apr-2013			Clostridium difficile antigens	Pending
P38317IE-EPC-PCT	Ireland	13715732.7	04-Apr-2013	2844283	12-Jun-2019	Clostridium difficile antigens	Granted
P38317NL-EPC-PCT	Netherlands	13715732.7	04-Apr-2013	2844283	12-Jun-2019	Clostridium difficile antigens	Granted
P38317US-D1-PCT	United States of America	15/130749	04-Apr-2013	9896514	20-Feb-2018	Clostridium difficile antigens	Granted
P38317US-PCT	United States of America	14/390528	04-Apr-2013	9315555	19-Apr-2016	Clostridium difficile antigens	Granted
P40308CHL-EPC-PCT	Switzerland & Liechtenstein	13802091.2	29-Nov-2013	2961846	10-Jan-2018	Crimean-Congo Haemorrhagic Fever virus antigenic composition	Granted
P40308DE-EPC-PCT	Germany	13802091.2	29-Nov-2013	2961846	10-Jan-2018	Crimean-Congo Haemorrhagic Fever virus antigenic composition	Granted
P40308FR-EPC-PCT	France	13802091.2	29-Nov-2013	2961846	10-Jan-2018	Crimean-Congo Haemorrhagic Fever virus antigenic composition	Granted
P40308GB-EPC-PCT	United Kingdom	13802091.2	29-Nov-2013	2961846	10-Jan-2018	Crimean-Congo Haemorrhagic Fever virus antigenic composition	Granted
P40308IN-PCT	India	8589/DELNP/2015	29-Nov-2013			Crimean-Congo Haemorrhagic Fever virus antigenic composition	Pending

P40308TR-EPC-PCT	Turkey	13802091.2	29-Nov-2013	2961846	10-Jan-2018	Crimean-Congo Haemorrhagic Fever virus antigenic composition	Granted
P40308US-PCT	United States of America	14/763622	29-Nov-2013	10059747	28-Aug-2018	Crimean-Congo Haemorrhagic Fever virus antigenic composition	Granted
P40500CN-PCT	China	201580019823.1	16-Apr-2015			Fluid collection device	Pending
P40500EP-PCT	European Patent Office	15718571.1	16-Apr-2015			Fluid collection device	Pending
P40500JP-PCT	Japan	2016-559519	16-Apr-2015	6543643	21-Jun-2019	Fluid collection device	Granted
P40500US-PCT	United States of America	15/304025	16-Apr-2015			Fluid collection device	Pending
P40501AU-PCT	Australia	2015257483	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing Tuberculosis	Pending
P40501BR-PCT	Brazil	BR112016025627-1	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing Tuberculosis	Pending
P40501CA-PCT	Canada	2947109	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing Tuberculosis	Pending
P40501CN-PCT	China	201580030469.2	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing Tuberculosis	Pending
P40501EP-D1-PCT	European Patent Office		07-May-2015			Biomarkers and Combinations Thereof for Diagnosing active	Not Yet Filed

						Tuberculosis	
P40501EP-PCT	European Patent Office	15722572.3	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing active Tuberculosis	Pending
P40501HK-D1-PCT	Hong Kong		07-May-2015			Biomarkers and Combinations Thereof for Diagnosing active Tuberculosis	Not Yet Filed
P40501HK-PCT	Hong Kong	17102807.0	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing Tuberculosis	Pending
P40501IN-PCT	India	201617037590	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing Tuberculosis	Pending
P40501US-PCT	United States of America	15/309348	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing Tuberculosis	Pending
P40501ZA-PCT	South Africa	2016/07663	07-May-2015			Biomarkers and Combinations Thereof for Diagnosing Tuberculosis	Pending
P40633AT-EPC-PCT	Austria	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633AU-PCT	Australia	2007283199	10-Aug-2007	2007283199	04-Mar-2013	Attenuated polio viruses	Granted
P40633BE-EPC-PCT	Belgium	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633CA-PCT	Canada	2660375	10-Aug-2007	2660375	03-Feb-2015	Attenuated polio viruses	Granted
P40633CHL-EPC-PCT	Switzerland & Liechtenstein	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted

P40633CN-PCT	China	20078003708 3.X	10-Aug-2007	20078003708 3.X	27-Mar-2013	Attenuated polio viruses	Granted
P40633DE-EPC-PCT	Germany	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633DK-EPC-PCT	Denmark	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633ES-EPC-PCT	Spain	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633FR-EPC-PCT	France	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633IE-EPC-PCT	Ireland	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633IN-PCT	India	1197/OELNP/ 2009	10-Aug-2007	279577	25-Jan-2017	Attenuated polio viruses	Granted
P40633IT-EPC-PCT	Italy	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633JP-PCT	Japan	523348/2009	10-Aug-2007	5222847	15-Mar-2013	Attenuated polio viruses	Granted
P40633LU-EPC-PCT	Luxembourg	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633NG-PCT	Nigeria	NG/C/2009/7 2	10-Aug-2007	NG/C/2009/7 2	31-Jul-2009	Attenuated polio viruses	Granted
P40633NL-EPC-PCT	Netherlands	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633SE-EPC-PCT	Sweden	07789191.9	10-Aug-2007	2049153	12-Dec-2012	Attenuated polio viruses	Granted
P40633US-C1-PCT	United States of America	14/053426	14-Oct-2013	9408903	09-Aug-2016	"Attenuated polio viruses"	Granted
P40633US-PCT	United States of America	12/377041	10-Aug-2007	8557252	15-Oct-2013	Genetically stable attenuated polioviruses comprising multiple mutations in domain V of the 5' noncoding region	Granted
P40633ZA-PCT	South Africa	2009/00986	10-Aug-2007	2009/00986	28-Apr-2011	Attenuated polio viruses	Granted
P40634AT-EPC-PCT	Austria	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634AU-PCT	Australia	2011350995	29-Dec-2011	2011350995	09-Mar-2017	"Inactivated poliovaccine"	Granted
P40634BE-EPC-PCT	Belgium	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted

						"	
P406348R-PCT	Brazil	112013017014-0	29-Dec-2011			"Inactivated poliovaccine"	Pending
P40634CA-PCT	Canada	2821859	29-Dec-2011			"Inactivated poliovaccine"	Pending
P40634CHL-EPC-PCT	Switzerland & Liechtenstein	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634CN-PCT	China	201180063532.4	29-Dec-2011	ZL 201180063532.4	20-Apr-2016	"Inactivated poliovaccine"	Granted
P40634DE-EPC-PCT	Germany	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634DK-EPC-PCT	Denmark	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634ES-EPC-PCT	Spain	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634FR-EPC-PCT	France	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634GB-EPC-PCT	United Kingdom	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634IE-EPC-PCT	Ireland	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634IN-PCT	India	5777/DELNP/2013	29-Dec-2011			"Inactivated poliovaccine"	Pending
P40634IT-EPC-PCT	Italy	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634JP-PCT	Japan	2013/546763	29-Dec-2011	5955860	24-Jun-2016	"Inactivated poliovaccine"	Granted
P40634LU-EPC-PCT	Luxembourg	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634NG-PCT	Nigeria	NG/C/2013/543	29-Dec-2011			"Inactivated poliovaccine"	Pending
P40634NL-EPC-PCT	Netherlands	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted
P40634RU-PCT	Russian Federation	2013135290	29-Dec-2011	2599453	10-Oct-2016	"Inactivated poliovaccine"	Granted
P40634SE-EPC-PCT	Sweden	11807966.4	29-Dec-2011	2658571	02-Mar-2016	"Inactivated poliovaccine"	Granted

						"	
P40634US-PCT	United States of America	13/977399	29-Dec-2011	9402892	02-Aug-2016	"Inactivated poliovaccine"	Granted
P40634ZA-PCT	South Africa	2013/04415	29-Dec-2011	2013/04415	26-Mar-2014	"Inactivated poliovaccine"	Granted
P41905EP-PCT	European Patent Office	17722136.3	27-Apr-2017			Method for detecting carbapenemase-producing bacteria	Pending
P41905US-PCT	United States of America	16/096917	27-Apr-2017			Detection method	Pending
P43964AU-PCT	Australia	2016217679	10-Feb-2016			Filovirus therapy	Pending
P43964GB-PCT	United Kingdom	1713151.7	10-Feb-2016			Filovirus therapy	Pending
P43964US-PCT	United States of America	15/549933	10-Feb-2016			Filovirus therapy	Pending
P44246AU-PCT	Australia	2017334293	29-Sep-2017			Assay for distinguishing between sepsis and systemic inflammatory response syndrome	Awaiting filing receipt
P44246CA-PCT	Canada	3036411	29-Sep-2017			Assay for distinguishing between sepsis and systemic inflammatory response syndrome	Pending
P44246EP-PCT	European Patent Office	17780869.8	29-Sep-2017			Assay for distinguishing between sepsis and systemic inflammatory response syndrome	Pending
P46448 (KCL managed)	European Patent Office	16813021.9	09-Dec-16			PBD antibacterial agents	Pending
P46450 (KCL managed)	Patent Cooperation Treaty	PCT/GB2018/51468	30-May-18			Antibiotic resistance breakers	Pending

P46448 (KCL managed)	United States of America	16/061295	09-Dec-16			PBD antibacterial agents	Pending
P44246HK-PCT	Hong Kong	19131229.7	29-Sep-2017			Assay for distinguishing between sepsis and systemic inflammatory response syndrome	Pending
P44246IN-PCT	India	201927013663	29-Sep-2017			Assay for distinguishing between sepsis and systemic inflammatory response syndrome	Pending
P44246US-PCT	United States of America	16/335830	29-Sep-2017			Assay for distinguishing between sepsis and systemic inflammatory response syndrome	Pending
P44246ZA-PCT	South Africa	TBC	29-Sep-2017			Assay for distinguishing between sepsis and systemic inflammatory response syndrome	Pending
P44957AU-PCT	Australia	2013365769	18-Dec-2013	2013365769	28-Jun-2018	Antimicrobial compounds, their synthesis and applications thereof	Granted
P44957BR-PCT	Brazil	BR112015014391-1	18-Dec-2013			Antimicrobial compounds, their synthesis and applications thereof	Pending

P44957CA-PCT	Canada	2894202	18-Dec-2013			Antimicrobia compounds, their synthesis and applications thereof	Pending
P44957CN-PCT	China	20138007098 4.4	18-Dec-2013	ZL2013800709 84.4	19-Jun-2018	Antimicrobia compounds, their synthesis and applications thereof	Granted
P44957EP-PCT	European Patent Office	13865950.3	18-Dec-2013			Antimicrobia compounds, their synthesis and applications thereof	Pending
P44957HK-PCT	Hong Kong	15111327.4	18-Dec-2013			Antimicrobia compounds, their synthesis and applications thereof	Pending
P44957IN-PCT	India	4011/CHENP/ 2015	18-Dec-2013			Antimicrobia compounds, their synthesis and applications thereof	Pending
P44957JP-PCT	Japan	2015-548841	18-Dec-2013	6533466	31-May-2019	Antimicrobia compounds, their synthesis and applications thereof	Granted
P44957US-PCT	United States of America	14/652714	18-Dec-2013	9783490	10-Oct-2017	Antimicrobia compounds, their synthesis and applications thereof	Granted

P45837AU-PCT	Australia	2016325583	23-Sep-2016			Coxiella burnetii antigens	Pending
P45837CA-PCT	Canada	2997670	23-Sep-2016			Coxiella burnetii antigens	Pending
P45837EP-PCT	European Patent Office	16775844.0	23-Sep-2016			Coxiella burnetii antigens	Pending
P45837US-PCT	United States of America	15/761012	23-Sep-2016			Coxiella burnetii antigens	Pending
P46804EP-PCT	European Patent Office	17754462.4	07-Aug-2017			Flavivirus diagnostic assay	Pending
P46804US-PCT	United States of America	16/324107	07-Aug-2017			Flavivirus diagnostic assay	Pending
Baxter#1	European Patent Office	10075524.8	01-Dec-00	2295968	19/09/2012	Pyrogenicity test for use with automated immunoassay systems	Granted
Baxter#1	Japan	2001-549078	01/12/2000			Pyrogenicity test for use with automated immunoassay systems	Pending
Baxter#1	Japan	2011-109920	01/12/2000			Pyrogenicity test for use with automated immunoassay systems	Pending
Baxter#1	United States of America	09/727561	01/12/2000	6696261	24/02/2004	Pyrogenicity test for use with automated immunoassay systems	Granted
Baxter#2	Australia	2006330562	20/12/2006	2006330562	02/05/2013	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted

Baxter#2	Brazil	PI0620434	20.12.06			Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	
Baxter#2	European Patent Office	6846727.3	20.12.06	1977252	05-Dec-12	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	
Baxter#2	European Patent Office	11003878	20.12.06	2360479	02-Apr-14	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	Canada	2633523	20.12.06			Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	
Baxter#2	China	20131025272 4	20.12.06	103901208	24.8.16	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	

Baxter#2	China	20068004887 2.00	20.12.06	101346630	17.7.13	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	Colombia	(ex-PCT/2006/US 62424)	20.12.06			Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	
Baxter#2	Hong Kong	8112758	20.12.06	1119243		Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	Hong Kong	12101704	20.12.06	1161638		Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	Hong Kong	15100025	20.12.06	1199753		Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted

Baxter#2	India	5332/DELNP/2008	20.12.06	297101	20.5.18	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	Japan	2008-547757	20.12.06	4686611	25.5.2011	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	Republic of Korea	20087017829	20.12.06	101352222	4.2.14	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	Mexico	2008008138	20.12.06			Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	
Baxter#2	Singapore	2012017133	20.12.06			Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	

Baxter#2	United States of America	13/293868	20.12.06	9023647	5.5.15	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	United States of America	14/679651	20.12.06	9671411	6.6.17	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	United States of America	11/613866	20.12.06	7736863	15.6.10	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	United States of America	12/767514	20.12.06	8058021	15.11.11	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted
Baxter#2	United States of America	12/767537	20.12.06	8053200	8.11.11	Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products	Granted

KCL#1	Patent Cooperation Treaty	PCT/GB2018/051468	30.05.2018			Antibiotic resistance breakers	Pending
KCL#1	Canada	(ex-PCT/GB2018/051468)	30.05.2018			Antibiotic resistance breakers	Pending
KCL#1	European Patent Office	18730054.6	30.05.2018			Antibiotic resistance breakers	Pending
KCL#1	Japan	(ex-PCT/GB2018/051468)	30.05.2018			Antibiotic resistance breakers	Pending
KCL#1	United States of America	(ex-PCT/GB2018/051468)	30.05.2018			Antibiotic resistance breakers	Pending
KCL#1	China	(ex-PCT/GB2018/051468)	30.05.2018			Antibiotic resistance breakers	Pending
KCL#2	United States of America	16/061295	09.12.2016			PBD antibacterial agents	Pending
KCL#2	European Patent Office	16813021.9	09.12.2016			PBD antibacterial agents	Pending

IN WITNESS of the above this Confirmation of Assignment has been executed on the date first above written.

NIGEL MAURICE PUGH
Notary Public
37 Southgate Street
Winchester
SO23 9EH
England
United Kingdom
+44(0)7771 977
nigel@notarywinche.

Signed on behalf of The Secretary of State for Health

[Signature]
name Alex Sienkiewicz


position DIRECTOR OF CORPORATE AFFAIRS

Signed witnessed and NOTARISED
before me *[Signature]*
NOTARY PUBLIC

Signed on behalf of Secretary of State for Health and Social Care

[Signature]
name CHRIS E. NWOGUH

position DEPUTY DIRECTOR, HEAD OF BUSINESS DEVELOPMENT.



Signed witnessed and NOTARISED before me

[Signature]
NOTARY PUBLIC

both at Porton Down Salisbury SP4 0JG
England
United Kingdom
on 16 MARCH 2020

Annex A

Statutory Instrument 2018 No. 378 ("The Secretaries of State for Health and Social Care and for Housing, Communities and Local Government and Transfer of Functions (Commonhold Land) Order 2018")

2018 No. 378

MINISTERS OF THE CROWN

**The Secretaries of State for Health and Social Care and for
Housing, Communities and Local Government and Transfer of
Functions (Commonhold Land) Order 2018**

Made 14th March 2018

Laid before Parliament 21st March 2018

Coming into force 11th April 2018

At the Court at Buckingham Palace, the 14th day of March 2018

Present,

The Queen's Most Excellent Majesty in Council

Her Majesty, in exercise of the powers conferred by sections 1 and 2 of the Ministers of the Crown Act 1975(a), is pleased, by and with the advice of Her Privy Council, to order as follows:

Citation and commencement

1.—(1) This Order may be cited as the Secretaries of State for Health and Social Care and for Housing, Communities and Local Government and Transfer of Functions (Commonhold Land) Order 2018.

(2) This Order comes into force on 11th April 2018.

Interpretation

2. In this Order—

“CLG function” means any function so far as—

- (a) it is transferred by article 8, or
- (b) it was entrusted to the Secretary of State for Communities and Local Government immediately before 8th January 2018 and has before the making of this Order been entrusted to the Secretary of State for Housing, Communities and Local Government;

“health function” means any function so far as—

- (a) it is transferred by article 4, or
- (b) it was entrusted to the Secretary of State for Health immediately before 8th January 2018 and has before the making of this Order been entrusted to the Secretary of State for Health and Social Care;

(a) 1975 c. 26. Section 1 was amended by section 20 of the Constitutional Reform Act 2005 (c. 4).

"instrument" includes Royal Charters, Royal Warrants, Orders in Council, Letters Patent, judgments, decrees, orders, rules, regulations, schemes, bye-laws, awards, licences, authorisations, consents, approvals, contracts and other agreements, memoranda and articles of association, certificates, deeds and other documents.

Incorporation of the Secretary of State for Health and Social Care

3.—(1) The person who at the coming into force of this Order is the Secretary of State for Health and Social Care and any successor to that person is by that name a corporation sole.

(2) The corporate seal of the Secretary of State for Health and Social Care—

- (a) is to be authenticated by the signature of a Secretary of State or a person authorised by a Secretary of State to act in that behalf, and
- (b) is to be officially and judicially noted.

(3) Every document purporting to be an instrument made or issued by the Secretary of State for Health and Social Care and to be—

- (a) sealed with the corporate seal of that Secretary of State authenticated in the manner provided for by paragraph (2), or
- (b) signed or executed by a person authorised by a Secretary of State to act in that behalf,

is to be received in evidence and to be deemed to be so made or issued without further proof, unless the contrary is shown.

(4) A certificate signed by the Secretary of State for Health and Social Care that an instrument purporting to be made or issued by—

- (a) the Secretary of State for Health and Social Care, or
- (b) the Secretary of State for Health,

was so made or issued is conclusive evidence of that fact.

(5) The Documentary Evidence Act 1868(a) applies in relation to the Secretary of State for Health and Social Care—

- (a) as if references to regulations and orders included references to any document, and
- (b) as if the officers mentioned in column 2 of the Schedule included any officer authorised to act on behalf of the Secretary of State.

Transfer of functions etc to the Secretary of State for Health and Social Care

4. The functions of the Secretary of State for Health are transferred to the Secretary of State for Health and Social Care.

5. There are transferred to the Secretary of State for Health and Social Care all property, rights and liabilities to which the Secretary of State for Health is entitled or subject at the coming into force of this Order.

Secretary of State for Health and Social Care: supplementary

6.—(1) Anything (including legal proceedings) which, at the coming into force of this Order, is in the process of being done by or in relation to the Secretary of State for Health may be continued by or in relation to the Secretary of State for Health and Social Care.

(2) Anything done (or having effect as if done) by or in relation to the Secretary of State for Health has effect, so far as necessary for continuing its effect after the coming into force of this Order, as if done by or in relation to the Secretary of State for Health and Social Care.

(a) 1868 c. 37.

(3) Any enactment or instrument passed or made before the coming into force of this Order has effect, so far as is necessary for the purposes of or in consequence of---

- (a) the transfer or entrusting to the Secretary of State for Health and Social Care of a health function, or
- (b) the transfer of anything by article 5,

as if references to (and references which are to be read as references to) the Secretary of State for Health were or included references to the Secretary of State for Health and Social Care.

(4) Documents or forms printed for use in connection with a health function may be used in connection with that function even though they contain (or are to be read as containing) references to the Secretary of State for Health; and for the purposes of the use of any such documents or forms after the coming into force of this Order, those references are to be read as references to the Secretary of State for Health and Social Care.

(5) In paragraphs (1) to (4), references to a Secretary of State include references to the department or an officer of that Secretary of State.

Incorporation of the Secretary of State for Housing, Communities and Local Government

7.—(1) The person who at the coming into force of this Order is the Secretary of State for Housing, Communities and Local Government and any successor to that person is by that name a corporation sole.

(2) The corporate seal of the Secretary of State for Housing, Communities and Local Government---

- (a) is to be authenticated by the signature of a Secretary of State or a person authorised by a Secretary of State to act in that behalf, and
- (b) is to be officially and judicially noted.

(3) Every document purporting to be an instrument made or issued by the Secretary of State for Housing, Communities and Local Government and to be---

- (a) sealed with the corporate seal of that Secretary of State authenticated in the manner provided for by paragraph (2), or
- (b) signed or executed by a person authorised by a Secretary of State to act in that behalf,

is to be received in evidence and to be deemed to be so made or issued without further proof, unless the contrary is shown.

(4) A certificate signed by the Secretary of State for Housing, Communities and Local Government that an instrument purporting to be made or issued by---

- (a) the Secretary of State for Housing, Communities and Local Government,
- (b) the Secretary of State for Communities and Local Government,
- (c) the First Secretary of State,
- (d) the Secretary of State for Transport, Local Government and the Regions,
- (e) the Secretary of State for Environment, Transport and the Regions, or
- (f) the Secretary of State for the Environment,

was so made or issued is conclusive evidence of that fact.

(5) The Documentary Evidence Act 1868 applies in relation to the Secretary of State for Housing, Communities and Local Government---

- (a) as if references to regulations and orders included references to any document, and
- (b) as if the officers mentioned in column 2 of the Schedule included any officer authorised to act on behalf of the Secretary of State.

Transfer of functions etc to the Secretary of State for Housing, Communities and Local Government

8. The functions of the Secretary of State for Communities and Local Government are transferred to the Secretary of State for Housing, Communities and Local Government.

9. There are transferred to the Secretary of State for Housing, Communities and Local Government all property, rights and liabilities to which the Secretary of State for Communities and Local Government is entitled or subject at the coming into force of this Order.

Secretary of State for Housing, Communities and Local Government: supplementary

10.—(1) Anything (including legal proceedings) which, at the coming into force of this Order, is in the process of being done by or in relation to the Secretary of State for Communities and Local Government may be continued by or in relation to the Secretary of State for Housing, Communities and Local Government.

(2) Anything done (or having effect as if done) by or in relation to the Secretary of State for Communities and Local Government has effect, so far as necessary for continuing its effect after the coming into force of this Order, as if done by or in relation to the Secretary of State for Housing, Communities and Local Government.

(3) Any enactment or instrument passed or made before the coming into force of this Order has effect, so far as is necessary for the purposes of or in consequence of—

- (a) the transfer or entrusting to the Secretary of State for Housing, Communities and Local Government of a CLG function, or
- (b) the transfer of anything by article 9,

as if references to (and references which are to be read as references to) the Secretary of State for Communities and Local Government were or included references to the Secretary of State for Housing, Communities and Local Government.

(4) Documents or forms printed for use in connection with a CLG function may be used in connection with that function even though they contain (or are to be read as containing) references to the Secretary of State for Communities and Local Government; and for the purposes of the use of any such documents or forms after the coming into force of this Order, those references are to be read as references to the Secretary of State for Housing, Communities and Local Government.

(5) In paragraphs (1) to (4), references to a Secretary of State include references to the department or an officer of that Secretary of State.

Transfer of functions etc from the Lord Chancellor to the Secretary of State

11. The functions of the Lord Chancellor under Part 1 of the Commonhold and Leasehold Reform Act 2002(a) (commonhold land) are transferred to the Secretary of State.

12. There are transferred to the Secretary of State for Housing, Communities and Local Government all property, rights and liabilities to which the Lord Chancellor is entitled or subject at the coming into force of this Order in connection with a function transferred by article 11.

Articles 11 and 12: supplementary

13.—(1) This article applies to—

- (a) a function transferred to the Secretary of State by article 11 (“a former LC function”), and
- (b) anything transferred by article 12.

(a) 2002 c. 15

(2) Anything (including legal proceedings) which, at the coming into force of this Order, is in the process of being done by or in relation to the Lord Chancellor may, so far as it relates to anything to which this article applies, be continued by or in relation to the Secretary of State.

(3) Anything done (or having effect as if done) by or in relation to the Lord Chancellor in connection with anything to which this article applies has effect, so far as necessary for continuing its effect after the coming into force of this Order, as if done by or in relation to the Secretary of State.

(4) Any enactment or instrument passed or made before the coming into force of this Order has effect, so far as is necessary for the purposes of or in consequence of anything to which this article applies, as if references to (and references which are to be read as references to) the Lord Chancellor were or included references to the Secretary of State.

(5) Documents or forms printed for use in connection with a former LC function may be used in connection with that function even though they contain (or are to be read as containing) references to the Lord Chancellor; and for the purposes of the use of any such documents or forms after the coming into force of this Order, those references are to be read as references to the Secretary of State.

(6) In paragraphs (2) to (5)---

(a) references to the Lord Chancellor are to be read as including references to the department or an officer of the Lord Chancellor, and

(b) references to the Secretary of State are to be read as including references to the department or an officer of the Secretary of State accordingly.

Validity of things done before coming into force of Order

14.---(1) This Order does not affect the validity of anything done (or having effect as if done) by or in relation to the Secretary of State for Health, the Secretary of State for Communities and Local Government or the Lord Chancellor before the coming into force of this Order.

(2) In paragraph (1) the reference to a Secretary of State or the Lord Chancellor includes a reference to the department or an officer of that Secretary of State or of the Lord Chancellor (as the case may be).

Consequential amendments

15. The Schedule has effect.

Richard Tilbrook
Clerk of the Privy Council

SCHEDULE

CONSEQUENTIAL AMENDMENTS

Article 15

PART 1

Amendments to primary legislation

Transport Act 1962 (c. 46)

1. In section 86(6A) of the Transport Act 1962(a), for "Communities and Local Government" substitute "Housing, Communities and Local Government".

(a) Section 86(6A) was inserted by S.I. 1976/1681 and amended by S.I. 1976/1775, 1997/2971, 2001/2568, 2002/2626 and 2006/1926.

Parliamentary Commissioner Act 1967 (c. 13)

2. In Schedule 2 to the Parliamentary Commissioner Act 1967(a)—

- (a) omit "Department for Communities and Local Government.",
- (b) in the entry for the Department of Health after "Health" insert "and Social Care", and
- (c) at the appropriate place insert "Ministry of Housing, Communities and Local Government".

Abortion Act 1967 (c. 87)

3. In section 2(2) of the Abortion Act 1967(b), after "Health" insert "and Social Care".

Food Act 1984 (c. 30)

4. In section 135(2)(a)(ii) of the Food Act 1984(c), after "Health" insert "and Social Care".

Town and Country Planning Act 1990 (c. 8)

5.—(1) The Town and Country Planning Act 1990 is amended as follows.

(2) In section 228(d), in subsections (1) and (7) and in the heading for "Communities and Local Government" substitute "Housing, Communities and Local Government".

(3) In the following provisions, for "Communities and Local Government" substitute "Housing, Communities and Local Government"—

- (a) section 245(1)(b)(e);
- (b) section 265(1)(d)(f).

(4) In paragraph 8(2) of Schedule 6(g), for "the Department for Communities and Local Government" substitute "the Ministry of Housing, Communities and Local Government".

Planning (Listed Buildings and Conservation Areas) Act 1990 (c. 9)

6. In paragraph 7(2) of Schedule 3 to the Planning (Listed Buildings and Conservation Areas) Act 1990(h), for "the Department for Communities and Local Government" substitute "the Ministry of Housing, Communities and Local Government".

Planning (Hazardous Substances) Act 1990 (c. 10)

7. In paragraph 7(2) of the Schedule to the Planning (Hazardous Substances) Act 1990(i), for "the Department for Communities and Local Government" substitute "the Ministry of Housing, Communities and Local Government".

-
- (a) Schedule 2 was substituted by S.I. 2011/2986. Other amendments have been made to Schedule 2 which are not relevant to this Order.
 - (b) Section 2(2) was amended by S.I. 1969/388 and by S.I. 1988/1843. Other amendments have been made to section 2(2) which are not relevant to this Order.
 - (c) In section 135(2)(a)(ii) the reference to the Secretary of State for Health was inserted by S.I. 1988/1843.
 - (d) Section 228 was amended by S.I. 1997/2971, 2001/2568, 2002/2626 and 2006/1926.
 - (e) Section 245(1)(b) was amended by S.I. 1997/2971, 2001/2568, 2002/2626 and 2006/1926.
 - (f) In section 265(1), paragraph (a) was repealed and paragraph (d) amended by S.I. 1997/2971; paragraph (d) was further amended by S.I. 2001/2568; paragraph (a) was inserted and paragraph (d) substituted by S.I. 2002/2626, and paragraph (d) was further substituted by S.I. 2006/1926.
 - (g) Paragraph 8(2) was amended by S.I. 1997/2971, 2001/2568, 2002/2626 and 2006/1926.
 - (h) Paragraph 7(2) was amended by S.I. 1997/2971, 2001/2568, 2002/2626 and 2006/1926.
 - (i) Paragraph 7(2) was amended by S.I. 1997/2971, 2001/2568, 2002/2626, and 2006/1926.

Transport and Works Act 1992 (c. 42)

8. In section 23(10) of the Transport and Works Act 1992(a), for "the Department for Communities and Local Government" in both places substitute "the Ministry of Housing, Communities and Local Government".

Regulation of Investigatory Powers Act 2000 (c. 23)

9. In Part 1 of Schedule 1 to the Regulation of Investigatory Powers Act 2000(b)---

(a) for paragraph 9A substitute---

"9A. The Ministry of Housing, Communities and Local Government.", and

(b) in paragraph 12 after "Health" insert "and Social Care".

Commonhold and Leasehold Reform Act 2002 (c. 15)

10. In the following provisions of the Commonhold and Leasehold Reform Act 2002, for "Lord Chancellor" in each place substitute "Secretary of State"--

(a) section 42(2) (power to approve ombudsmen schemes);

(b) section 62(1) and (2) (power to give financial assistance in relation to advice etc)(c);

(c) section 64(2) (making of regulations under Part 1 of the Act).

Enterprise Act 2002 (c. 40)

11. In section 213(5A)(d) of the Enterprise Act 2002(d), after "Health" insert "and Social Care".

Domestic Violence, Crime and Victims Act 2004 (c. 28)

12. In Schedule 9 to the Domestic Violence, Crime and Victims Act 2004 (authorities within Commissioner's remit)---

(a) omit paragraph 1ZA(e),

(b) in paragraph 3 after "Health" insert "and Social Care", and

(c) after paragraph 8A insert---

"8B. The Ministry of Housing, Communities and Local Government."

Corporate Manslaughter and Corporate Homicide Act 2007 (c. 19)

13. In Schedule 1 to the Corporate Manslaughter and Corporate Homicide Act 2007---

(a) omit "Department for Communities and Local Government",

(b) at the end of the entry for the Department of Health insert "and Social Care", and

(c) at the appropriate place insert "Ministry of Housing, Communities and Local Government".

(a) Section 23(10) was amended and paragraph (a) substituted by S.I. 1997/2971; section 23(10) was further amended by S.I. 2001/2568, 2002/2626 and 2006/1926.

(b) Schedule 1 was amended by S.I. 2007/3224, 2009/229 and 2009/2748. Paragraph 9A was inserted by S.I. 2006/1926. Other amendments have been made to Schedule 1 which are not relevant to this Order.

(c) Section 62(1) was amended by section 319(1) of the Housing and Regeneration Act 2008.

(d) Section 213(5A) was inserted by S.I. 2006/3363. Other amendments have been made to section 213(5A) which are not relevant to this Order.

(e) Paragraph 1ZA was inserted by S.I. 2006/1926.

Crossrail Act 2008 (c. 18)

14. In the following provisions of the Crossrail Act 2008, for "Communities and Local Government" substitute "Housing, Communities and Local Government"----

- (a) section 12(6) (in the definition of "appropriate Ministers");
- (b) section 54(5);
- (c) paragraph 2(8) of Schedule 5 (in the definition of "appropriate Ministers");
- (d) paragraph 37(2) of Schedule 7.

Coroners and Justice Act 2009 (c. 25)

15. In the following provisions of the Coroners and Justice Act 2009, after "Health" insert "and Social Care"—

- (a) section 18(2)(a);
- (b) section 20(1)(n).

Care Act 2014 (c. 23)

16. In section 111(1)(d) of the Care Act 2014, after "Health" insert "and Social Care".

Investigatory Powers Act 2016 (c. 25)

17. In Schedule 4 to the Investigatory Powers Act 2016, in column (1) of the table in Part 1, in the entry for the Department of Health after "Health" insert "and Social Care".

High Speed Rail (London – West Midlands) Act 2017 (c. 7)

18. In the following provisions of the High Speed Rail (London – West Midlands) Act 2017, for "Communities and Local Government" substitute "Housing, Communities and Local Government"—

- (a) section 64(5);
- (b) paragraph 5(9) of Schedule 16 (in the definition of "appropriate Ministers");
- (c) paragraph 30 of Schedule 17 (in the definition of "appropriate Ministers").

Digital Economy Act 2017 (c. 30)

19. In the following provisions of the Digital Economy Act 2017, for "Communities and Local Government" substitute "Housing, Communities and Local Government"----

- (a) paragraph 8 of Schedule 4;
- (b) paragraph 3 of Schedule 5;
- (c) paragraph 2 of Schedule 6;
- (d) paragraph 9 of Schedule 8.

PART 2

Amendments to secondary legislation

20. In each of the following provisions, after "of Health" in each place insert "and Social Care"—

- (a) regulations 4(2)(a) and 5(a)(i) of the Abortion Regulations 1991(a);
- (b) column 2 of Schedule 6 to the Welfare Food Regulations 1996(b);
- (c) column (2) of the Schedule to the Building Societies (Business Names) Regulations 1998(c), in relation to the entries for "abortion", "Health Centre" and "Health Service", and "Pregnancy Termination";
- (d) regulations 7(6)(ab), 8(7)(aa), 9(12)(ab) and 13(3)(a)(i) and (ii) of the Radiation (Emergency Preparedness and Public Information) Regulations 2001(d);
- (e) article 2 of, and paragraph 1 of Schedule 1 to, the Medicines and Healthcare Products Regulatory Agency Trading Fund Order 2003(e);
- (f) column 2 of the table in Schedule 2 to the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc) Regulations 2004(f);
- (g) the Schedule to the Primary Medical Services (Sale of Goodwill and Restrictions on Sub-contracting) Regulations 2004(g);
- (h) regulations 18(1)(a)(iii) and 22(3)(d) of the Justification of Practices Involving Ionising Radiation Regulations 2004(h);
- (i) Part 1 of the Schedule to the Damages (Government and Health Service Bodies) Order 2005(i);
- (j) article 3(c)(i) of the NHS Business Services Authority (Awdurdod Gwasanaethau Busnes y GIG) (Establishment and Constitution) Order 2005(j);
- (k) paragraph (a) of the definition of "health authority" in regulation 2 of the Major Accident Off-Site Emergency Plan (Management of Waste from Extractive Industries) (England and Wales) Regulations 2009(k);
- (l) column (1) of the table in Schedule 1 to the Infrastructure Planning (Applications: Prescribed Forms and Procedure) Regulations 2009(l);
- (m) regulation 20(9) of the Care Quality Commission (Registration) Regulations 2009(m);
- (n) column (1) of the table in Schedule 2 to the Infrastructure Planning (Compulsory Acquisition) Regulations 2010(n);
- (o) column (1) of the table in Part 2 of Schedule 2 to the Regulation of Investigatory Powers (Communications Data) Order 2010(o);
- (p) column (1) of the table in Part 1 of the Schedule to the Regulation of Investigatory Powers (Directed Surveillance and Covert Human Intelligence Sources) Order 2010(p);
- (q) regulations 10(1) and 11(1) of the Health Protection (Part 2A Orders) Regulations 2010(q);

-
- (a) S.I. 1991/489, amended by S.I. 2002/2879; there are other amending instruments but none is relevant.
 - (b) S.I. 1996/1434, amended by S.I. 2004/2311; there are other amending instruments but none is relevant.
 - (c) S.I. 1998/3186, to which there are amendments not relevant to this Order.
 - (d) S.I. 2001/2975, amended by S.I. 2013/235; there are other amending instruments but none is relevant.
 - (e) S.I. 2003/1076, to which there are amendments not relevant to this Order.
 - (f) S.I. 2004/629; relevant amending instruments are S.I. 2004/3215, 2009/2230, 2010/2389, 2011/680 and 2013/363.
 - (g) S.I. 2004/906, to which there are amendments not relevant to this Order.
 - (h) S.I. 2004/1769, amended by S.I. 2013/235; there are other amending instruments but none is relevant.
 - (i) S.I. 2005/474, to which there are amendments not relevant to this Order.
 - (j) S.I. 2005/2414, amended by S.I. 2006/632; there are other amending instruments but none is relevant.
 - (k) S.I. 2009/1927, amended by S.I. 2013/235; there are other amending instruments but none is relevant.
 - (l) S.I. 2009/2264, amended by S.I. 2013/522; there are other amending instruments but none is relevant.
 - (m) S.I. 2009/3112, to which there are amendments not relevant to this Order.
 - (n) S.I. 2010/104, amended by S.I. 2013/522; there are other amending instruments but none is relevant.
 - (o) S.I. 2010/480, to which there are amendments not relevant to this Order.
 - (p) S.I. 2010/521, to which there are amendments not relevant to this Order.
 - (q) S.I. 2010/658, amended by S.I. 2013/235.

- (r) regulation 1(3) of the Health Protection (Notification) Regulations 2010(a);
- (s) regulations 22(4)(c), 26(2)(e) and 35(6)(b)(i) of the Water Supply (Water Quality) Regulations 2010(b);
- (t) regulation 12(1) and (2)(a) of, and paragraph 7 of the Schedule to, the Medical Profession (Responsible Officers) Regulations 2010(c);
- (u) in the entry for Public Health England in column (1) the table in Schedule 1 to the Infrastructure Planning (Changes to, and Revocation of, Development Consent Orders) Regulations 2011(d);
- (v) paragraph 2 of Schedule 4 to the National Health Service (Clinical Commissioning Groups) Regulations 2012(e);
- (w) the definition of "Public Health England" in regulation 213(1) of the Human Medicines Regulations 2012(f);
- (x) regulation 16(a) of the Local Authority (Public Health, Health and Wellbeing Boards and Health Scrutiny) Regulations 2013(g);
- (y) the definition of "postgraduate dental dean or director of postgraduate dental education" in regulation 29 of the National Health Service (Performers Lists) (England) Regulations 2013(h);
- (z) paragraph (e) of the definition of "responsible person" in regulation 8(3) of the Local Authorities (Public Health Functions and Entry to Premises by Local Healthwatch Representatives) Regulations 2013(i);
- (aa) regulation 4(1)(h) of the National Health Service (Clinical Commissioning Groups – Payments in Respect of Quality) Regulations 2013(j);
- (bb) in Schedule 2 to the Company, Limited Liability Partnership and Business Names (Sensitive Words and Expressions) Regulations 2014(k)–
 - (i) in column (2) in Part 1, in relation to the entry in column (1) for "NHS", and
 - (ii) in column (2) in Part 2;
- (cc) column 1 in Schedule 1 to the Infrastructure Planning (Interested Parties and Miscellaneous Prescribed Provisions) Regulations 2015(l), in the entry for Public Health England;
- (dd) regulations 12(5)(e), 13(7)(d) and 14(3)(a) of the Control of Major Accident Hazards Regulations 2015(m);
- (ee) in each place in column 2 of the table in the Schedule to the Proceeds of Crime Act 2002 (References to Financial Investigators) (England and Wales) Order 2015(n);
- (ff) paragraph 1 of Schedule 2 to the Medicines (Products for Human Use) (Fees) Regulations 2016(o), in the definition of "the MHRA portal";
- (gg) the definition of "Public Health England" in regulation 2(1) of the Water Supply (Water Quality) Regulations 2016(p).

-
- (a) S.I. 2010/659, amended by S.I. 2013/235.
 - (b) S.I. 2010/994, amended by S.I. 2013/235; there are other amending instruments but none is relevant.
 - (c) S.I. 2010/2841, amended by S.I. 2013/391.
 - (d) S.I. 2011/2055, amended by S.I. 2013/522; there are other amending instruments but none is relevant.
 - (e) S.I. 2012/1631, to which there are amendments not relevant to this Order.
 - (f) S.I. 2012/1916, to which there are amendments not relevant to this Order.
 - (g) S.I. 2013/218, to which there are amendments not relevant to this Order.
 - (h) S.I. 2013/335, to which there are amendments not relevant to this Order.
 - (i) S.I. 2013/351, to which there are amendments not relevant to this Order.
 - (j) S.I. 2013/474.
 - (k) S.I. 2014/3140, to which there are amendments not relevant to this Order.
 - (l) S.I. 2015/462, to which there are amendments not relevant to this Order.
 - (m) S.I. 2015/483.
 - (n) S.I. 2015/1853, to which there are amendments not relevant to this Order.
 - (o) S.I. 2016/190.
 - (p) S.I. 2016/614, to which there are amendments not relevant to this Order.

21. In each of the following provisions, after "for Health" in each place insert "and Social Care"---

- (a) paragraph 48(2) of Schedule 9 and paragraph 38(2) of Schedule 10 to the Income Support (General) Regulations 1987(a);
- (b) paragraph 44(2) of Schedule 2 to the Family Credit (General) Regulations 1987(b);
- (c) paragraph 42(d) of Schedule 3 and paragraph 39(2) of Schedule 4 to the Disability Working Allowance (General) Regulations 1991(c);
- (d) paragraph 47(2) of Schedule 7 and paragraph 36(2) of Schedule 8 of the Jobseeker's Allowance Regulations 1996(d);
- (e) paragraph 42(2) of Schedule 3 and paragraph 39(2) of Schedule 4 to the Housing Renewal Grants Regulations 1996(e);
- (f) regulations 3(1), (2) and (3) of the Good Laboratory Practice Regulations 1999(f);
- (g) item 12(e) in table 6 in regulation 19 of the Tax Credits (Definitions and Calculation of Income) Regulations 2002(g);
- (h) article 3 of the Medicines and Healthcare Products Regulatory Agency Trading Fund Order 2003(h);
- (i) article 2(2) of the Crime (International Co-operation) Act 2003 (Designation of Prosecuting Authorities) Order 2004(i);
- (j) the definition of "Appointing Authority" in paragraph 2 of the Schedule to the Postgraduate Medical Education and Training Board (Members - Removal from Office) Rules Order 2004(j);
- (k) paragraph 2(1)(j)(i) and (k)(i) of Schedule 2 to the Dairy Produce Quotas Regulations 2005(k);
- (l) paragraphs 2 to 6 of Schedule 1 to the Water Supply (Flouridation Indemnities) England Regulations 2005(l);
- (m) paragraph 44(2) of Schedule 5 and paragraph 40(2) of Schedule 6 to the Housing Benefit Regulations 2006(m);
- (n) paragraph 45(2) of Schedule 4 and paragraph 40(2) of Schedule 5 to the Council Tax Benefit Regulations 2006(n);
- (o) paragraph 45(2) of Schedule 8 and paragraph 37(2) of Schedule 9 to the Employment and Support Allowance Regulations 2008(o);
- (p) regulations 9A(1) and (4) and 10(1)(c) and (2) of the Social Security (Information-sharing in relation to Welfare Services etc) Regulations 2012(p);
- (q) in the Schedule to the Council Tax Reduction Schemes (Default Scheme) (England) Regulations 2012(q), paragraph 46(2) of Schedule 8 and paragraph 43(2) of Schedule 10;

-
- (a) S.I. 1987/1967, relevant amending instruments are S.I. 1996/1776 and S.I. 2008/3157.
 - (b) S.I. 1987/1973, amended by S.I. 1990/1774; there are other amending instruments but none is relevant.
 - (c) S.I. 1991/2887, to which there are amendments not relevant to this Order.
 - (d) S.I. 1996/207, amended by S.I. 2008/3157; there are other amending instruments but none is relevant.
 - (e) S.I. 1996/2890, to which there are amendments not relevant to this Order.
 - (f) S.I. 1999/3106.
 - (g) S.I. 2002/2006, amended by S.I. 2010/2914; there are other amending instruments but none is relevant.
 - (h) S.I. 2003/1076.
 - (i) S.I. 2004/1034; amended by S.I. 2012/146; there are other amending instruments but none is relevant.
 - (j) S.I. 2004/3410, to which there are amendments not relevant to this Order.
 - (k) S.I. 2005/465, to which there are amendments not relevant to this Order.
 - (l) S.I. 2005/920.
 - (m) S.I. 2006/213, amended by S.I. 2008/3157; there are other amending instruments but none is relevant.
 - (n) S.I. 2006/215, amended by S.I. 2008/3157; there are other amending instruments but none is relevant.
 - (o) S.I. 2008/794, to which there are amendments not relevant to this Order.
 - (p) S.I. 2012/1483, amended by S.I. 2013/454; there are other amending instruments but none is relevant.
 - (q) S.I. 2012/2886, to which there are amendments not relevant to this Order.

- (r) in both columns in the Schedule to the Public Interest Disclosure (Prescribed Persons) Order 2014(a);
- (s) Part 1 of Schedule 4 to the Criminal Justice and Data Protection (Protocol No 36) Regulations 2014(b);
- (t) regulations 3(1) and (3) and 8(a) of the Social Security (Information-sharing) (NHS Payments and Remission of Charges etc) (England) Regulations 2015(c);
- (u) Parts 2 and 3 of Schedule 1 to the Criminal Justice (European Investigation Order) Regulations 2017(d);
- (v) paragraph 3(2)(o) of Schedule 2 to the NHS Counter Fraud Authority (Establishment, Constitution, and Staff and Other Transfer Provisions) Order 2017(e).

22. In regulation 4(2)(a) of the Abortion Regulations 1991, for "Richmond House, 79 Whitehall, London, SW1A 2NS" substitute "39 Victoria Street, London SW1H 0EU".

EXPLANATORY NOTE

(This note is not part of the Order)

This Order in Council is made under sections 1 and 2 of the Ministers of the Crown Act 1975. It makes provision for, and in connection with, the transfer of functions from the Secretary of State for Health to the Secretary of State for Health and Social Care and from the Secretary of State for Communities and Local Government to the Secretary of State for Housing, Communities and Local Government. It also makes provision for the transfer of functions in relation to commonhold land.

Article 3 provides for the incorporation of the Secretary of State for Health and Social Care as a corporation sole and for the authentication of the corporate seal and execution and certification of documents. Article 4 transfers functions from the Secretary of State for Health to the Secretary of State for Health and Social Care. Article 5 transfer property, rights and liabilities. Article 6 makes supplementary provision.

Article 7 provides for the incorporation of the Secretary of State for Housing, Communities and Local Government as a corporation sole and for the authentication of the corporate seal and execution and certification of documents. Article 8 transfers functions from the Secretary of State for Communities and Local Government to the Secretary of State for Housing, Communities and Local Government. Article 9 transfers property, rights and liabilities. Article 10 makes supplementary provision.

Article 11 transfers functions in relation to commonhold land from the Lord Chancellor to the Secretary of State, and article 12 transfers property, rights and liabilities in connection with those functions to the Secretary of State for Housing, Communities and Local Government. Article 13 makes supplementary provision.

Article 14 makes provision preserving the validity of anything done by or in relation to the Secretary of State for Health, the Secretary of State for Communities and Local Government and the Lord Chancellor before the coming into force of this Order.

Article 15 and the Schedule make consequential amendments to primary and secondary legislation.

(a) S.I. 2014/2418, amended by S.I. 2015/1981; there are other amending instruments but none is relevant.

(b) S.I. 2014/3141, amended by S.I. 2014/3191; there are other amending instruments but none is relevant.

(c) S.I. 2015/124.

(d) S.I. 2017/730.

(e) S.I. 2017/958.

Nothing in this Order alters the functions of the Welsh Ministers, the Scottish Ministers or the devolved authorities in Northern Ireland

A full impact assessment has not been produced for this instrument as no, or no significant, impact on the private, voluntary or public sector is foreseen.

© Crown copyright 2018


Printed and published in the UK by The Stationery Office Limited under the authority and superintendence of Jeff James, Controller of Her Majesty's Stationery Office and Queen's Printer of Acts of Parliament.

£6.00

UK201803071021 03/2018 19585

<http://www.legislation.gov.uk/id/uk/si/2018/1378>

ISBN 978-0-11-116749-6



9 780111 167496

RECORDED: 09/19/2019

PATENT
REEL: 052144 FRAME: 0293